Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice
DOI: https://doi.org/10.2147/dddt.s445415
IF: 4.3188
2024-03-18
Drug Design Development and Therapy
Abstract:Ji-Eun Song, 1 Hae-Jin Ko, 2 A-Sol Kim 1 1 Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea; 2 Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea Correspondence: Hae-Jin Ko, Department of Family Medicine, School of Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Korea, Tel +82 53 200 6578, Fax +82 53 200 5480, Email Purpose: Anti-obesity medications (AOMs), along with lifestyle interventions, are effective means of inducing and maintaining weight loss in patients with obesity. Although the efficacy of AOMs has been reported, there have been no direct comparisons of these drugs. Therefore, in the present study, we aimed to compare the efficacy of all the AOMs available in Korea in a real-world setting. Patients and Methods: The body weight and composition of 205 adults treated with phentermine, phentermine/topiramate, liraglutide, naltrexone/bupropion, lorcaserin, or orlistat for at least 6 months were analyzed at 2 month intervals. The prevalence of the achievement of a ≥ 5% weight loss and the changes in body composition were compared between participants using each AOM at each visit. Results: A total of 132 (64.4%) participants achieved ≥ 5% weight loss within 6 months (prevalence of ≥ 5% weight loss after 6 months: phentermine, 87.2%; phentermine/topiramate, 67.7%; liraglutide, 58.1%; naltrexone/bupropion, 35.3%; lorcaserin, 75%; orlistat, 50%). At each visit, after adjustment for age, sex, and baseline body weight, phentermine use was associated with a significantly higher prevalence of ≥ 5% weight loss than the use of the other AOMs, except for liraglutide. There were significant differences in the body weight, body mass index and body fat mass among the AOM groups by visit (P for interaction < 0.05), but not in their waist circumference, skeletal muscle mass, percentage body fat, or visceral fat area. Conclusion: All the AOMs were effective at inducing and maintaining weight loss, in the absence of significant changes in muscle mass, over a 6 month period, and the short-term use of phentermine and the long-term use of phentermine/topiramate or liraglutide would be practical choices for the treatment of obesity. However, further, large-scale studies are necessary to confirm these findings. Keywords: anti-obesity medication, body composition, weight loss, body weight maintenance, obesity Obesity is a chronic condition that predisposes toward and exacerbates a range of diseases, including type 2 diabetes mellitus, cardiovascular disease, stroke, peripheral vascular disease, sleep apnea, fatty liver disease, osteoarthritis, infertility, depression, anxiety, and types of cancer. 1 Decades have passed since the World Health Organization (WHO) defined obesity as the "new epidemic of the 21st century" and emphasized that obesity should be managed as a chronic disease. 2 However, the number of people with obesity continues to increase worldwide, 3 and South Korea is no exception. In Korea, the prevalence of obesity significantly increased by 1.18-fold over the decade from 2009, from 32.6% to 38.5%, using a definition of a body mass index (BMI) ≥ 25 kg/m 2 , in accordance with the Asia-Pacific World Health Organization (WHO) criteria. 4,5 Obesity not only represents a health problem for individuals, but also a substantial public health issue and economic burden. Therefore, it is essential to identify effective treatments. A loss of body weight of 3–5% has been shown to reduce blood glucose concentration, improve quality of life, and reduce the risk of cardiovascular disease; and a 5–10% weight loss over 6 months has been recommended as an initial goal to achieve health benefits. 6,7 Lifestyle interventions, including dietary, exercise, and behavioral modifications, are the key methods of achieving weight loss. In addition, pharmacologic interventions should be considered for patients living with obesity or those who are overweight with obesity-related comorbidities, particularly if they are unable to achieve weight loss through lifestyle interventions alone. 8 Weight loss and long-term weight maintenance are essential for the successful treatment of obesity. However, it has been reported that approximately 80% of people who achieve a weight loss of ≥10% are not successful at maintaining their weight loss over a period of 1 year. 9 Interestingly, a meta-analysis showed no difference in the maintenance of weight loss between a group that lost weight through diet and exercise, and a -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal